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SOMMAIRE
Environ 3% de la population mondiale dont 1.5 millions de canadiens souffrent du
diabète. La morbidité associée au diabète de type I ou II (diabète insulino-dépendant
ou non-insulino-dépendant), résulte de complications sérieuses, telles que;
microangiopathie, néphropathie, neuropathie et rétinopathie. La prevalence de tous
les types de rétinopathie dans la population diabétique augmente avec la durée du
diabète et l’âge du patient.
Des données soutenant la participation du système kallikreine-kinine dans la
pathogenèse du diabète a été obtenue à partir de patients diabétiques et de modèles
animaux de diabète par plusieurs groupes. Les kinines sont des agents vasoactifs
efficaces dans la microcirculation, où elles produisant les effets par des récepteurs
sur le muscle lisse des microvaissaux ou des cellules endothéliales suite à une
réaction inflammatoire ou un dommage tissulaire.
Des données de la littérature ont démontré que le système kallikreine-kinine est
exprimé au niveau des yeux de lapins et de porcs. Aussi, à l’aide d’analyses RT-PCR
et Southern blot, l’expression et la localisation des differentes composantes de ce
système tels que la kallikreine tissulaire, le kininogene de faible poids moléculaire et
les récepteusrs B1 et récepteurs B2 à forte densité ont été identifiées dans la rétine
humaine. En outre, l’hybridation in situ a identifié la localisation cellulaire des ARN
messagers des composantes de ce système dans les tissus oculaires et dans les
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cellules endothéliales des vaisseaux sanguins oculaires humains. Cependant, il n’y a
aucune étude sur la fonction physiologique du système kallikreine-kinine et son rôle
potentiel dans le développement de la rétinopathie diabétique au niveau de l’oeil. Le
but de cette étude était d’étudier le rôle des kinines dans la régulation du tonus
vasculaire rétinien, avec trois objectifs spécifiques:
.i) déterminer la nature des récepteurs aux kinines impliqués en utilisant des
agonistes et antagonistes selectifs,
ii) investïguer les voies de signalisation impliquées dans l’effet vasoactif des
kinines dans la rétine, et
iii) étudier l’effet de la bradykinine (BK) et de la des-Arg9-BK sur le tonus des
vaisseaux rétiniens chez le rat aduit Wistar diabétique suite à l’injection de
streptozotocine (SIZ).
Les résultats de cette étude montrent que:
j) la BK dilate les vaisseaux rétiniens chez les rats contrôles et diabétique, et l’effet
vasodilatateur de la BK passe par la stimulation des récepteurs B2,
ii) la des-Arg9-BK ne dilate pas les vaisseaux rétiniens chez le rat contrôle,
iii) la des-Arg9-BK dilate les vaisseaux rétiniens chez les rats diabétiques et l’effet
vasodilatateur de la des-Arg9-BK passe par la stimulation des récepteurs B1,
iv) l’effet vasodilatateur des kinins implique une G-proteins (G/G0),
y) la libération de l’oxyde nitrique et l’augmentation du calcium intracellulaire par
l’influx à partir du milieu extracellulaire ne sont pas impliqués dans les effets de
la BK et la des-Arg9-BK. Mais,
Vvi) l’augmentation de Ca2 intracellulaire à partir des réserves intracellulaires
sensible et insensible à l’1P3 et la libération de prostaglandine ‘2 (prostacycline;
PGI2), métabolite de la voie de la cyclooxygénase, sont impliquées dans les
effets de la BK et la des-Arg9-BK.
Nos résultats fournissent pour la première fois des évidences fonctionnelles directes
que le système kallikreine-kinine joue un rôle crucial dans la régulation du tonus
vasculaire rétinien et que ce système peut avoir un rôle principal durant les premières
étapes de développement de la rétinopathie diabétique.
Mots clés: récepteurs B2, récepteurs B1, rétinopathie diabétique, vasodilatation.
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SUMMARY
About 3% of the world population including 1.5 million Canadians suffer from
diabetes. The morbidity associated with long-standing diabetes of either type I or II
(insulin-dependent or non-insulin-dependent diabetes mellitus respectively) results
from a number of serious complications, namely microangiopathy, nephropathy,
neuropathy and retinopathy. The prevalence of retinopathy in the diabetic population
increases with the duration of diabetes and is directly correlated with patient age.
The true cause of diabetic microvascular disease is unknown. There is increasing
evidence, from diabetic animal models and diabetic patients, which supports the
involvement of tissue kallikrein in diabetes mellitus. Kinins are potent vasoactive
agents in the microcirculation, producing effects through receptors on microvessel
smooth muscle or endothelial celis following inllammatory insuit or tissue damage.
Previous studies have demonstrated that kallikrein-like enzymatic activity exists in
tissue homogenates of rabbit and swine eyes. Furthermore, it has been shown by
molecular studies that mRNAs for key components of the kallikrein-kinin system,
including tissue kallikrein and low molecular weight kininogen, are present in human
ocular tissues. In addition, high levels of kinin B1 and B2 receptors have been
detected in human retina. Also, in situ hybridization lias identified mRNAs for the
components of the kallikrein-kinin system in ocular tissues and in endothelial ceils of
human ocular blood vessels. However, there lias been no study on the physiologic
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function of the kallikrein-kinin system in ocular tissues and its potentiai foies ifl the
deveiopment of diabetic retinopathy.
The aim of the current study was to investigate the effect of kinins on retinai vesse!
tone, with three specific objectives:
j) to establish which receptors mediate the vascuiar response to kinins using
se!ective agonists and antagonists,
ii) to determine which signa! transduction pathways mediate the vascu!ar effects of
kinins in the retina of heaithy aduit maie Wistar rats, and
iii) to study the effect of Bradykinin (BK) and des-Arg9-BK on retinai vesse! toile in
the aduit streptozotocin (STZ)-diabetic rat.
The present study shows that:
i) BK dilates retinal vessels in control and STZ-diabetic rats,
ii) the vasodi!ator effect of BK is mediated by stimulation of B2 receptors,
iii) des-Arg9-BK is without effect on retina! vessel tone in control rats, but
des-Arg9-BK dilates retinal vessels in STZ-diabetic rats,
iv) the vasodi!ator effect of des-Arg9-BK is mediated by stimulation of B1 recep
tors,
y) downstream of B1 or B2 receptors, the vasodilator effect of kinins is transduced
by G/G0-proteins, and
vi) the release of nitric oxide (NO) or the influx of extrace!!u!ar Ca2 are not invo!
ved in the vasodilation evoked by either BK or des-Arg9-BK. In contrast, libera
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tion of Ca2 from both intracellular, 1P3-sensitive and non-1P3-sensitive, pools
are involved as well as the release of prostaglandin 12 (prostacyclin; PGI2).
This study is the first to provide direct ftnctional evidence that the kallikrein-kinin
system may play a role in the retinal circulation, and may be a factor early in the
pathological development of diabetic retinopathy.
Key words: B2 receptors, B1 receptors, diabetic retinopathy, vasodilation.
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1CHAPTER I
1. INTRODUCTION
1.1. DIABETES MELLITUS
Diabetes mellitus is a chronic disorder of carbohydrate, fat and protein metabolism.
About 3% of the world population, including 1.5 million Canadians, suffer from
diabetes, making it one of the most common noncommunicable diseases ‘. This
disease can be categorised into two common variants (Type I and Type II) which
differ in their pattern of inheritance, responses to insulin, origins, and less commonly
in specific genetic defects of 13-cell function (Table I) 2 & (Table II) ‘. Type I
diabetes, also called IDDM, and previously referred to as juvenile onset diabetes,
accounts for about 10 % of ail cases of primary diabetes. This is mainly due to a
defect in insulin secretion. Most patients (80%-90%) have type II diabetes, also
termed NIDDM and previously referred to as aduit onset diabetes. Its onset follows a
defect in the response to insulin due to either a non responsive insulin receptor or to
a defect in the transduction machinary .
It should be stressed that while the two catagories of diabetes have different
pathologic mechanisms, the long-term complications produced in blood vessels,
kidneys, nerves, and eyes are the same. Such complications are the major causes of
morbidity and finally death from diabetes’.
2TABLE I. CATEGORIES 0f DIABETES MELLITUS
Primary Diabetes
- Type I (insulin-dependent diabetes mellitus, IDDM)
- Type II (non-insulin-dependent diabetes mellitus, NIDDM)
- Genetic defects of f3-cell function (including maturity-onset diabetes of the young [MODY])
Secondary Diabetes
- Infections (e.g.,congenital rubella)
- Endocrinopathies (e.g., pituitary tumours)
- Drugs (e.g.,corticosteroids)
- Other genetic disorder (e.g., Down’s syndrome)
- Gestational diabetes mellitus
Modified from the report of the Executive Committee on the Diagnosis and Classification of Diabetes
Mellitus: Diabetic Care 20: 1183-1197, 1997 2
TABLE II. COMPARISON 0f TYPE I VS TYPE II DIABETES MELLITUS
TYPE I (IDDM) TYPE II (NIDDM)
Clinical Onset <20 yr Onset >30 yr
Decreased blood insulin Normal or increased blood insulin
Pathogenesis Autoimmunity Insulin resistance
Severe insulin deficiency Relative insulin deficiency
Modified from pathologic basis of disease. W.B. Saunders Company. Philadelphia. 9 13-929, 1999’.
1.1.1. TYPE I DIABETES MELLITUS
Ibis form of diabetes resuits from a severe drop in the level of circulating insulin due
to a reduction in 3-ceil mass. Three interrelated mechanisms are responsible for islet
ceil destruction: genetic susceptibility, autoimmunity, and an environmental insuit ‘.
31.1.2. TYPE II DIABETES MELLITUS
Pathogenesis of type II diabetes mellitus remains enigmatic. Genetic factors are even
more important in type II than in type I diabetes. The two metabolic defects that
characterize type II diabetes are: a derangement in 3-ce11 secretion of insulin and a
decreased response of peripheral tissues to insulin (insulin resistance) 1•
1.1.3. PATHOLOGY 0F DIABETES
The morbidity associated with long-standing diabetes of both types resuits from a
number of serious complications, namely microangiopathy, nephropathy, neuropathy
and retinopathy . There is extreme variability among patients with regards to the
time of onset of these complications, their severity, and the particular organ(s) that
are involved. In those whom are able to control well their diabetes, the onset may be
delayed . The cause of diabetic microvascular disease has not been established ‘. The
overproduction of cytokines including IL-113 and TNFŒ following an autoimmune
response leads to the destruction of pancreatic 13-celis and consequently the induction
of diabetes mellitus type I “. Furthermore, most of the available experimental and
clinical evidence suggests that the complications are a consequence of the metabolic
derangement, in particular the hyperglycemia “s. The oxidative stress following
hyperglycemia, may activate NF-iB which induces kinin B1 receptors. The latter is
generally under-expressed in normal conditions but it is highly inducible by
4inflammatory mediators . In addition, there is evidence to Support the invoivement of
the kallikrein-kinin system in diabetes meilitus 6• Both the overproduction of
cytokines and hyperglycemia stimulate the kallikrein-kinin system which is known
to promote arteriolar vasodilation ‘.
1.2. THE RETINA AND ITS BLOOD VESSELS
The retina is a thin, multilayered sheet of fleurai tissue that unes the inner aspect of
the posterior two-thirds of the wall of the ocuiar globe. It extends aimost as far
anteriorly as the ciiiary body, ending at that point in a ragged edge termed the ora
serrata. The outer surface of the sensory retina is apposed to the retinal pigment
epithelium and thus associated with Bruch’s membrane, the choroid, and the sciera
(Fig. 1) 8,9• The inner surface of the retina is in contact with the vitreous .
The retina receives its biood supply from two sources: the choriocapillaris
immediateiy outside of Bruch’s membrane, which supplies the outer third of the
retina; and branches of the centrai retinai artery, which suppiy the inner two-thirds
(Fig. 2). The capillaries of the retina vary in diameter from about 3 to 6 tm and they
are surrounded by a thick basal lamina, pericytes, and endothelial ceils. The retinal
biood vessels have a non-fenestrated endotheiium as do cerebral blood vessels. Such
an endotheiiai anatomy aiiows oniy extremeiy smali molecules such as 02 and C02
to pass into or out of the retina. It forms part of the biood-retinai barrier and regulates
the selective exchange of material and celis between the retina and the biood . In
5contrast, in other tissues, the clefts between the capillary endothelial celis are wide
open, therefore almost ail dissolved substances of the plasma can pass from the
blood into the tissues . The blood-retinal barrier in its entirety consists of two
anatomic characteristics: 1) tight junctions between the endothelial ceils of the retinal
vessels, 2) tight junctions between the retinal pigment epithelial celis . The blood
retinal barrier serves to maintain the proper ionic balance required for retinal
function The retina has the highest demand for 02 per gram tissue in the body. A
marked drop in the supply of 02 to the retina can resuit in iscliemia and the
pathological manifestations of disease such as diabetic retinopathy .
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FIGURE 2. The retina and its blood vessels (the branches from the choriocapillaries and central
retinal attery). In right hand, the structure of the retinal capillaries, from outside: basal lamina,
pericytes, and endothelial cells .
$1.3. OCULAR DIABETIC COMPLICATIONS
1.3.1. CLASSIFICATION AND INCIDENCE 0F DIABETIC
RETINOPATHY
Visual impairment leading to total blindness is among the most feared consequences
of long-standing diabetes This disease is currently the fourth leading cause of
acquired blindness in Western countries “s. is estimated that if a patient is
diagnosed as a diabetic at age 30, there is a 10% chance he wiÏl have some degree of
diabetic retinopathy by age 37 and up to 90% chance by age 55 ‘. The ocular
involvement may take the form of cataract formation, glaucoma or retinopathy . The
prevalence of ail types of retinopathy in the diabetic population increases with the
duration of diabetes and patient age . With advances in therapy, the life span of
diabetic patients bas improved, but the prevaience of secondary retinal disease has
greatly increased. Approximateiy 60% of diabetic patients develop retinopathy 15 to
20 years after their original diagnosis. furthermore, about 2% of the diabetic
population have visual impairment, severe enough to be considered legafly blind,
that is attributable to retinopathy o There are two forms of diabetic retinopathy
known as nonproliferative and proliferative retinopathy
91.3.2. NONPROLIFERATIVE DIABETIC RETINOPATHY
Early in the course of diabetic retinopathy, certain physiologic abnormalities are
seen. These include impaired autoregulation of the retinal vasculature, alterations in
retinal blood flow, and breakdown of the blood-retinal barrier . Retinal
microvascular changes that occur in nonproliferative retinopathy are limited to the
confines of the retina and do not extend beyond the retinal limiting membrane .
Characteristic findings include dilation of veins, microaneurysms, intraretinal
hemorrliages, diffuse edema, and focal exudates . The nonperfusion following
impaired autoregulation of the retinal vasculature produces hypoxia which can later
lead to proliferative retinopathy 3.10•
1.3.3. PROLIFERATIVE DIABETIC RETINOPATHY
The proliferative stage of diabetic retinopathy is subdivided into a proliferative phase
(neovascularization) and a contraction (cicatricial) phase 3.b0• The neovascularization
occurs in response to severe ischemia and hypoxia of the retina 3,10 The new
capillaries contain both endothelial celis and pericytes but are incompletely formed
and poorly supported o.
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1.3.4. VASODILATION IN DIABETIC RETINOPATHY
Changes in vascular flow and caliber begin very early after injury and develop at
varying rates, depending on the severity of the injury ‘. In the retinal circulation,
pericytes play a contractile function. Thus, pericyte degeneration in early stages of
diabetic retinopathy as a consequence of diabetes leads to vasodilation
Furthermore, retinal vessel damage due to diabetes stimulates the overproduction of
cytokines derived from lymphocytes and macrophages, and activation of Nf-KB or
the release of vasodilator agents which promote arteriolar vasodilation The
vasodilation is associated with retinal ischemia. It is perhaps an attempt by the retinal
circulation to releave the ischemia through vasodilation leading to increased blood
flow.
1.3.5. RETINOPATHY IN STZ-DIABETIC RAT MODEL
Ocular complications following diabetes have been reported in a variety of
laboratory species 1214rn In animal models as in human, the deveiopment of diabetic
retinopathy depends on the duration and severity of hyperglycemia. The rat as a
model of diabetic retinopathy offers advantages over other large animais in terms of
cost and housing requirements and relatively rapid onset of significant anatomic
criteria such as capiiiary cell loss. Although, because of the short life span of rats ail
changes that occur in the human retina due to diabetes do not appear in the rat, but
the early stages of diabetic retinopathy such as blood-retinal barrier breakdown and
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degenerative changes in pericytes have been demonstrated in the diabetic rat and
have been partly ascribed to VEGF 13,15 The vasodilator agents which mediate early
vasodilation have flot been established
1.4. THE KALLIKREIN-MNIN SYSTEM
The kallikrein-kinin system includes the kinins, their precursors (HMWK, LMWK,
and 1-kininogen), and their relative enzymes including plasma and tissue kallikreins,
T-kininogenase, kininase I, kininase 16-23•
1.4.1. MNIN BIOSYNTHESIS
Kinins are potent (subnanomolar Kd), short-lived (30 seconds or less) mediators.
They belong to a small family of structurally related 9-11 amino acid peptides
including BK, kallidin (KD; Lys-BK), T-kinin (IYe-Ser-BK; exclusively in rats), and
des-Arg-kinins (Table III) 16-26rn
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Bradykinin (BK) Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH
Ka1lidn Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH
T-Kinin Ile-Ser-Arg-Pro-Pro-GIy-Phe-Ser-Pro-Phe-Arg-OH
des-Arg9.BK Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-OH
Modified from Brain kallikrein-kinin system: from receptors to neuronal pathways and physiological
functions. Handbook of chemical neuroanatomy. 16: peptide receptors, part I. 241-300 16
BK and KD are generated following the proteolytic cleavage of their respective
precursors, HMWK and LMWK by plasma and tissue kallikreins 22.23 (Fig. 3). A
single gene codes for plasma kaÏlikrein, whereas tissue kallikrein is a member of a
multigene family that shows different patterns of tissue-specific gene expression 22
T-kinin was identified exclusively in the rat 24.25 and could be generated from T
kininogen under the enzymatic action of T-kininogenase 26• Kinins stimulate B1 or B2
receptors on the celi surface to produce their biological effects 21,22
TABLE III. PRIMARY STRUCTURE 0F MAMMALIAN KININS
123 456789
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Ancestor Gene
Gene T (rat)
/
z
Kininogen (LMW)
Gene K
B1 receptor
NH2
:2::. Extracellular
Intracellular
COOH
FIGURE 3. Kinin formation and inactivation. Ail the components of the kallikrein-kinin system
are shown in this diagram. The B1 receptor is flot readily expressed undet normal physiotogical
condition, it can be upregulated during chronic pathological states (e.g. inflammation,
hyperthermia, diabetes and epilepsy) 16 See text for details.
T-kininogen Kininogen (HMW)
T-Kininogenase Kallikrein J
Aminopeptidase I Aminopeptidase
T—kinin ......+.... * BK B2receptor
T-Kinin, Kallidin, BK
Kininase Il
‘OOH
Kininase II
Inactive Metabolites ‘ des-Arg-Kinins
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1.4.2. MNIN METABOLISM
Metabolic degradation is an important mechanism by which kinin action is
terminated. Kinins are broken down by a group of amino- , carboxy- and
endopeptidases found in blood, tissues and biological fluids 1622,27,28 (fig. 4). In
plasma and arterial walls, kinins are metabolized by carboxy-terminal degradation 29•
Kininase I (carboxypeptidase N of plasma or carboxypeptidase M of ceil
membranes) removes the C-terminal Arg and generates the des-Arg-kinin
homologues. Kininase II (also named angiotensin-I-converting enzyme, ACE), a
dipeptidyl carboxypeptidase, liberates the C-terminal Phe8-Arg9 and Ser6-Pro7 in a
sequential order 16• Kininase I metabolites are also kininase II substrates 27•
Kininase I
(carboxypeptidase N ,and carboxypeptidase M)
Kallidin
Lys-Arg’-Pro2-Pro3-G1y4-Phe5-Ser6-Pro7-Phe8-Arg9
(ACE)
Kininase II
ENZYME TISSUE
Kininase I Carboxypeptidase N Serum 30
Carboxypeptidase M ccli membrane3’
Kininase II Angiotensin oenverting enzyme (ACE) Membrane,Serum,
Endothelium, Brain,
Kidney, Lung,
cerebrospinai fluid 32,33
fIGURE 4. Principal kininases: Theit cleaving sites for bradykinin and kallidin, the tissues where high activites
are found 16
15
1.4.3. BIOLOGICAL EFFECTS
The biological effects of kinins include contraction or relaxation of smooth muscle,
effects on epithelial ion transport, actions on endothelial celis and promotion of
arteriolar vasodilation. Kinins participate in the acute inflammatory response of
microvasculature and aid in tissue repair The control of celi function and
mitogenesis are generally mediated via stimulation of B2 receptors
1.4.4. MNIN RECEPTORS
Kinins interact with their ceil surface G-protein coupled receptors (Fig. 5) to produce
a variety of biological effects, such as vasodilation, stimulation of celi proliferation,
production of pain and inllammatory responses 22
16
FIGURE 5. The dog B1 receptof amino acid sequence. Each circle represents an amino acid
residue with the single letter code inset. The transmembrane domains are designated by Roman
numerals. Clear circles indicate identical residues between dog and human B1 receptors. Asterisks
designate potential phosphorylation sites. Modified from molecular cloning and pharmacological
charactetization of the canin Bi and B2 bradykinin receptors. Bio!. Chem. 382: 123-129 17
There are at least two types of kinin receptors. They are designated B1 and B2
receptors Although, the existence of a B3 receptor was suggested in the
pulmonary tissue of guinea pig, but later the same group showed that it is invalid
By in situ hybridization the B1 receptor gene was localised to human chromosome 14
q 32.1-q32.2 38, in close proximity to the human B2 receptor gene mapped to
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chromosome 14 in hand q32 41,42• The sequence of kinin receptors lias seven
hydrophobic segments which form transmembrane helices .
B1 receptors were described for the first time in the isolated rabbit aorta They have
now been documented in isolated preparations taken from the cardiovascular, urinary
as well as from intestinal systems, and in cultured ceils of vascular, endothelial,
mesangial, tracheal, bone and fibroblast origin 3536,37,43• Although the B1 receptor is
constitutively present and functional in the canine cardiovascular system 13, in the
vas deferens and stomach of the mouse , this receptor is generally under-expressed
in normal conditions but it is highly inducible by infiammatory mediators such as
bacterial lipopolysaccliaride, interleukins, overproduction of cytokines and growth
factors 20,46
B2 receptors have been identified for the first time in rabbit isolated jugular veins
using pharmacological in vitro assays -‘. B2 receptors mediate the majority of in vivo
effects of kinins, including bronchoconstriction, hypotension, acute inflammatory
reactions, pain and hyperalgesia 36.47, Both B1 as well as B2 receptors have been
shown to mediate vasodilation
A comparison of B1 and B2 receptors according to size and interspecies homology is
presented in Table IV 16, The amino acid sequence of the human B1 receptor (353
amino acid protein) is 36% identical to the amino acid sequence of the human B2
receptor (364 amino acid protein). The percent homology between human and rat B2
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receptors is $0.6 and B1 receptors is 70.6. The natural agonists for B2 receptors are
BK and KD, and for B1 receptors the natural agonists are des-Arg’°-KD and des
Arg9-BK. Highly potent and selective peptide as well as non-peptide agonists and
antagonists for B2 receptors and only peptide selective agonists and antagonists for
B1 receptors are availabie. No nonpeptide B1 receptor antagonists have been
described . The peptide antagonist D-Arg- [Hyp3,Thi5,D-Tic7,Oic8,des-Arg9] -
BK([desArg’°]-Hoel4O lias been introduced as a selective B1 receptor antagonist ‘
and Hoe-140 as a selective B2 receptor antagonist ‘.
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TABLE IV. BIOCHEMICAL FEATURES AND PHARMACOLOGY 0F MNIN RECEPTORS”
Receptor B2 B,
Family Rhodopsin superfamily of
G-protein-coupled receptors ‘
Rhodopsin superfamily of
G-protein-coupled receptors
Number of
amino acids
(molecular wt.)
rat 366 (41.0 to 41.7 kDa) 50
human 364 (41.0 to 41.5 kDa) M
mouse 366 (41.5 kDa) 52
rabbit 367 (41.5 kDa)
rat 337 (38.4 kDa) 16
human 353 (40.4 kDa)
mouse 334 (38kDa) -
rabbit 352 (39.5 kDa) 6
Homology (%)
Between human and rat
Between human and mouse
Between human and rabbit
Between rabbit and rat
Between rabbit and mouse
Between mouse and rat
80.6
81.7
81.7
79.8
82.3
90.7
70.6
72.9
76.4
69.7
74.2
$8.4
Signal
transduction
mechanism
Phospholipase A,, C and D,
cAMP, cGMP, ion channels
Phospholipase A and C
Order of potency
of natural agonists
BK»des-Arg’-BK
KD»des-Arg10-KD
des-Arg’-BK»BK
des-Arg10-KD»KD
Peptide-selective
agonist
Ph’P(CH2NH)Arg9-BK 57 Sar[D-Phe’]des-Arg9-BK 58
Non-peptide-selective FR190997
agonist
Peptide-selective Hoe-140 .
antagonist
FR 173657
FR 167344
LF 16.0335
Bradyzide
- Hoe-140 is D-Arg-[Hyp, Thi5,D-Tic7, Oic’]-BK .
- FR190997 is ($-[2,6-dichloro3-[N-[(E)-4(N-methylcarbamoyl)cinnamidoacetyl]-N-methyl-
aminolbenzyloxy] -2-methyl-4-(2-pyridylmethoxy)quinoline)6°
- FR167344 is (3-bromo-8-[2,6-dichloro-3-[N-[(E0-4-(n,n-dimethylcarbamoyl)cinnamidoacetylJ-N-
methylamino]benzyloxy]-2-methylimidazo[1 ,2-aJpyridine hydrochloride)6’
- FR173657 is
dichlorobenzyloxy]-2-methylquinoline) 6
- LF1 6.0335 is (1 -[[3-[(2,4-dimethylquinolin-8-yl)oxymethylJ-2,4-dichloro-phenyljsulphonylj-2(S)-
[[4-[(aminoiminomethyl)phenylcarbonyl]pjperazjn-1-ylÏcarbonyllpyrroljdine)62
- Bradyzide is ((2S)-1-[4-(4-benzhydrylthiosemicarbazido)-3-nitrobenzenesulfonyl]pyrrolidine-2-
carboxylic acid[2-(2-dimethyl-aminoethyl)methylamino]ethyl]amide)63
Non-peptide-selective
antagonist
flot available
[Leu’]des-Arg9-BK
Lys [Leu’]des-Arg9-BK
AcLysJD-Na17,I1e’Jdes-
Arg -BK59
flot available
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1.5. VASCULAR SIGNAL TRANSDUCTION PATHWAYS
The signal initiated by the binding of kinins to their receptors on the ceil surface is
transduced by G-proteins to intracellular pathways (fig. 6). In general, kinin
receptors activate Gaq/1 1 and Gai to stimulate intracellular pathways 16,64•
Second messengers
Kinins
.
.
Cytoplasm
FIGURE 6. The patbway for G-protein dependent signal transduction. KR, kinin receptors; G, G
protein incluing its three subunites (a, 13 and y). See text for details .
Kinins stimulate a variety of intracellular pathways depending on cellular types.
Activation of intracellular pathways by kinins resuits in the accumulation of cAMP
or cGMP, activation of phospholipases A2, C or D. These second messengers will
then produce the release of prostaglandins or NO, the opening of ion channels, and
Celi membrane
.
+
4r
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release of inositol phosphates or DG from membrane inositol phospholipids. The
resuit is mobilization of [Ca2]1 and activation of several isoforms of PKC 22.66.67
Moreover, it is also suggested that the activation of protein tyrosine kinases and
phosphatases as well as a MAP kinase are involved in kinin-mediated signal
transduction 6g-70
1.5.1. MNIN-STIMULATED RELEASE 0F NITRIC OXIDE
Kinins could stimulate L-arginine tlirough the kinin receptors on the surface of
endothelial ceils to release NO 22,7i Nitric oxide is a lipophulic compound, therefore
it does not require a ceil surface receptor to mediate its action on vascular smooth
muscle. Indeed, NO produced by the endothelium probably moves by diffusion into
the contiguous vascular smooth muscle. The NO derived from L-arginine activates
GC in smooth muscle celis leading to accumulation of cGMP which mediates
vascular relaxation 72 (Fig. 7).
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Endothelial Ccli
Vascular Smooth
Muscle CeIl
Kinins
FIGURE 7. Nitric oxide and vascular smooth muscle ceils. Production of endothelium-derived
nitric oxide from L-arginine. R, kinin receptors ; NO, nitric oxide; OC, guanylyl cyclase; cGMP,
cyclic guanosine monophosphate; GTP, guanosine triphosphate 72
Nitric oxide
(NO)
+
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1.5.2. MNIN-STIMULATED INCREASE 0f INTRACELLULAR CALCIUM
Kinin-stimulated increase of [Ca2] can be achieved via extracellular influx or
through release of Ca2 from intraceilular stores There are five possible routes for
Ca2 entry into endotheliai ceils including receptor-operated, voltage-gated Ca2
channels, Ca2 leak channels, stretch-activated Ca2 channels, and Na/Ca2
exchange Kinins increase Ca2 influx into endothelial ceils by opening ion
channels . Furthermore, mediated by the 1P3 pathway, endothelial ceil Ca2 can be
increased by kinins (Fig. 8). Following stimulation of kinin receptors, PLC acts upon
PIP2 to generate DG and 1P3. Subsequentiy, 1P3 mobilizes intraceliular Ca2 from
internai stores to induce its effects Whiie a DG-activated PKC allows plasma
membrane influx of extracellular Ca2
24
Celi membrane
MNINS
FIGURE 8. The phosphatidylinositol pathway. R, kinin receptors; GP, G-protein; PIP2,
phosphatidyl-inositol 4,5-diphosphate; 1P3 , inositol triphosphate; DG, diacylglycerol; PKC, protein
kinase C
PIP%
‘P3
reticulum
Ca2
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1.5.3. MNIN-STIMULATED RELEASE 0F PROSTACYCLIN
Kinins could stimulate phospholipids through kinin receptors on endothelial celis to
produce AA, a 20 carbon, unsaturated, fatty acid formed from phospholipids in the
celi membrane by PLA2 . Subsequently, AA is metabolized by cyclo-oxygenases
including COX1, a constitutively expressed isoform that is involved in a range of
physiological functions, and the COX2 isoform which is inducible and expressed by
extracellular stimuli such as pro-inftamatory cytokines in different celis. Further
along the pathway, endoperoxides are metabolized by prostacyclin synthetase to
produce PGI2 (Fig. 9a & 9b)73. The synthesis of PGI2 occurs predominantly in the
endothelium and causes an increase of AC activity leading to the formation of
vasodilator cAMP from ATP
Blood
R
JJ. Endothelial
AA celi
cox
PGI2
FIGURE 9a. Prostacyclin (PG12) and vascular smooth muscle ceils. Kinins cause the release of
metabolites of Arachidonic acid (AA), PGI2, through activation of its specific endothelial receptor.
AC, adenylate cyclase; cAMP, cyclic adenosin monophosphate: ATP, adenosine triphosphate; KR,
kinin receptors; cox, cyclo-oxygenases
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Phospholipids
Phospholipase-A2
PROSTAGLANDINS
PGE2, PGD2, PGF2
HYDROPEROXY AND
HYDROXY FATFY ACIDS
Arachidonic acid
Cyclo-oxygenase
Endoperoxides
isomerase
Prostacyclin
synthetase
lipoxygenase
PROSTACYCLIN
(PGI2)
Vasodilation
THROMBOXANE-A2
FIGURE 9b. Arachidonic acid and its metabolites ‘. See text for information.
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1.6. THE KALLIKREIN-MNIN SYSTEM IN RELATION TO THE EYE
Previous studies have demonstrated that the kallikrein-like enzymatic activities exist
in tissue homogenates of rabbit and swine eyes Later, another group, usÏng RT
PCR, Southern blot analyses, and in sitit hybridization histochemistry, identified the
expression and localization of components of the kallikrein-kinin system in human
retina, choroid, cillary body, optic nerve, and endothelial cells of ocular blood
vessels 76 b date, there has flot been a study on the physiological function of the
kallikrein-kinin system in ocular tissues and its potential roles in the development of
the diabetic retinopathy.
2. HYPOTHESIS
Kinins are present in the retina, and kinins are known to be strong vasodilators. I
hereby propose the hypothesis that B2 receptors mediate vasodilation in the healthy
rat, and that early in diabetes kinin B1 receptors are induced and potentiate the
vasodilator effect of kinins in the retinal circulation.
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3. MM
To investigate the capacity for and mechanism of vasodilation produced by kinins in
the retinal circulation of diabetic rats and their healthy control.
4. SPECIFIC OBJECTIVES
My specific objectives are to:
1) investigate the effect of BK and des-Arg9-BK on retinal vesse! tone in the healthy
and STZ diabetic rat.
2) establish the receptors which mediate the vascular effects of kinins in the healthy
and diabetic retina.
3) detemiine the signal transduction pathways which mediate the vascular effects of
kinins in the retinal circulation.
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CHAPTER II
1. MATERIALS & METHOBS
1.1. BIOLOGICAL MODEL
Male Wistar rats (150-250g); age (37-52 days), were purchased from Charles River
(Saint Constant, Québec) and used as the control group. They were kept in our
animal facilities at 22 °C, 12 h light/dark cycle and fead with Rodent Laboratory
Chow # 5001 (Purina company, Canada) aU libituni.
For the diabetic group, Wistar rats were fasted overnight and made diabetic
following intraperitoneal injection of a single dose of STZ (65 mg/kg) dissolved in
sodium citrate (pH 4.5). STZ is known to cause DNA alkylation and subsequent
DNA strand breaks in pancreatic islet celis. This induces an insulitis and produces a
mode! of insulin-dependent diabetes mellitus Only rats with blood glucose 20
mM were considered diabetic. Also, the same rats showed polyuria after thay
became hyperglycemic. To measure the blood glucose, the rat’s tait was washed with
warm water and dried. Then, it was pricked and its blood glucose measured using
test strips (Roche company, Québec).
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1.2. EXPERIMENTAL PROTOCOL
The blood glucose of rats was evaluated just before the rats were decapitated to
remove their eyes. The eyes were enucleated and placed immediately in ice-cold
Krebs buffer (pH 7.4) of the following composition in mM: 120 NaCl, 4.5 KC1, 2.5
CaC12, 1.0 MgSO4, 27 NaHCO3, 1.0 KH2PO4, and 10 glucose. A circular incision
was made in the posterior segment of the eye near the ora serrata to remove the
anterior segment and vitreous body with minimal handiing of the retina. The
remaining eyecup was fixed with pins to a wax base containing 270 .il of Krebs
buffer (pH 7.35-7.45) and maintained at 37°C. The preparations were allowed to
stabilize for 15 mins. The outer vessel diameter was recorded with a video camera
and responses were quantified by a digital image analyser (Scion image) . A first
measure was made and considered as baseline. Afterwards, U-46619 was used to
apply a tone to retinal vessels before measuring the effect of kinins. A concentration
response curve (Fig. 10) was made, and 1 tM U-46619 was considered optimal for
the rest of the experiments. In a first set of experiments, the vessels were pretreated
with U-46619 (1iM), then cumulative concentration-response curves to BK and des
Arg9-BK in the control and diabetic groups were made. The agonists or antagonists
were used and vascular diameter was recorded before and after topical application of
each concentration of agent, at which time a stable response was achieved. The
responses are expressed as percent change in the outer diameter of the vessel
compared to U-46619 constricted vessels. It should be noted that in the present
study, our aim was to investigate the changes of diameter of the retinal veins. Veins
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have a larger overail diameter than corresponding arteries. Therefore, we chose the
vessels which appeard to have larger diameter.
1.3. CHEMICAL AGENTS
For this study, we used the following products: BK, a peptide-selective agonist for
the B2 receptor 57; des-Arg9-BK, a peptide-selective agonist for the B1 receptor
Hoe-140, a peptide-selective antagonist for the B2 receptor 49; and des-Arg’°-Hoe
140, a peptide-selective antagonist for the B1 receptor were purchased from
Peninsula laboratories (California). GdC13, a channel blocker ; STZ, a DNA
aikylating agent 75; U-46619, a stable thromboxane A2 mimetic and a vasoconstrictor
agent ° ; L-NAME, irreversible inhibitor of eNOS and a reversible inhibitor of
iNOS81 ; L-745.337, a specific COX-2 inhibitor 82; TPC, a PGI2 synthase inhibitor 83
and BHQ, specifically mobilizes Ca2 from 1P3-sensitive Ca2 stores by inhibiting
microsomal and sarcoplasmic reticulum Ca2-ATPase activity 84 were purchased
from Sigma. cADP-ribose which functions as a physiological regulator of Ca2
release and which mobilizes Ca2 from internai pools that are distinct from 1P3—
sensitive poois 85 and NF023, a selective and direct G-protein antagonist for a
subunits of the G0/G group $6 were from Calbiochem (California).
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1.4. STATISTICAL ANALYSIS
Each set of experiments were conducted on 3-8 rats, where n represents the number
of rats which were used. Ml resuits are expressed as mean ± SEM. Resuits are
analysed using Student’s t-test for paired samples and a one-way analysis of variance
(ANOVA) followed by the Dunnett test was used for multiple comparisons with
control group. A probability of p<O.O5 was considered statistically significant.
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CHAPTER III
1. RESULTS
The resuits of this study are divided into two parts. The first part has been conducted
in the healthy rat and the second part in the STZ-diabetic rat. Throughout the
experiments, U-46619 was used to give vessels tone and thus allow vasodilation to
be studied. In an initial set of experiments, a dose-response cuwe was constructed for
U-46619 to set the optimal concentration to use in the experiments. U-46619 was
applied serially to retinal preparations with concentrations ranging from 1 nM to 1
mM (Fig. 10). U-46619 induced a dose-dependent vasoconstriction of rat retinal
vessels. The vasoconstrictor effect was significant (j<O.O5, n=4) at concentrations
100 nM. The optimal concentration of U-46619 was decided to be 1 tM which
induces vascular tone similar to phsiological levels.
120
20
0
1 nM lOnM lOOnM liiM lOpM 100M lmM
U-46619
FIGURE 10. Dose-response curve for the effect of U-46619 on retinal vessel diameter. U-
46619, was applied at a serial concentration from 1 nM to lmM for 10 mïns to apply tone to the
retinal vessels. Resuits are expressed as mean ± SEM of data obtained from 4 separate retinas (4
rats). (*p<o.o5, n=4) compared to the baseline measure.
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1.1. CONTROL RAT
The following experiments were done in control healthy rat retinas, with the aim to
investigate the effect of BK on retinal vesse! diameter
1.1.1. EFFECT 0F BRADYMNIN ON RETINAL VESSEL TONE
After a baseline measure was taken, and U-46619 (1iM) was applied, retinas were
treated with serial concentrations of BK ranging from 100 pM to 10 nM. Treatment
duration for each concentration was 15 mins (Fig. 11). The resuits show that BK
induces a dose-dependent relaxation of retinal vessels following the vasoconstrictor
effect of U-46619. The vasodilator effect of BK is significant (p<0.05, n=13) starting
at a concentration of 100 pM.
*
160
*
140
*
120
100
E E.
_
1 iM lOOpM mM l0nM
U-46619 BK
FIGURE 11. Effect of BK on the control rat retinal vessel diameter. A baseline measure was
obtained. Then, U-46619 (1IM) was used and the second measure was obtained, after, BK was
applied at a serial concentration from 100 pM to 10 nM for 15 mins and the diameter of the vessels
was measured each time. (*p<O.OS. n=13) compared to the vasocostrictor effect of U-46619.
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1.1.2. EFFECT 0F des-Arg9-BRADYMNIN ON RETINAL VESSEL TONE
b determine the effect of des-Arg9-BK on control rat retinal vesse! diameter, U-
466 19 was used to constrict retinal vessels after which serial concentrations of des
Arg9-BK were applied over concentrations ranging from 10 pM to 10 nM, with a
treatment duration of 15 mins (Fig. 12). Resuits show that des-Arg9-BK does flot
affect (p>.0.05, n=7) retina! vessel diameter following the vasoconstrictor effect of U-
466 19. Even at a concentration 100 times higlier than what is needed of BK to
induce retinal vasodi!ation (des-Arg9-BK (10 nM) vs BK (100 pM)).
120
3 100
$01flliflli
1 jiM lOpM lOOpM mM lOnM
U-46619 des-Arg9-BK
FIGURE 12. Effect of des-Arg9-BK on the control rats retinal vessel diameter. A baseline measure
was obtained and then U46619 was used after 10 mins the second measurement was done. after that a
serial concentration of des-Arg9-BK ranging from 10 pM to 10 nM with a treatment duration of 15
mins was added. The diameter of the vessels was measured each time. The effect of des-Arg9-BK
compared with the vasoconstrictor effect of U-46619 (n=7).
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1.1.3. B2 RECEPTOR ANTAGONISM
To determine which kinin receptor mediates vasodilation evoked by BK under
healthy conditions, the following set of experiments were conducted. Retinal vessels
were vasoconstricted using U-46619 (1 liM). Afterwards, retinas were pretreated
with Hoe-140 (10 1iM), the B2 receptor specific antagonist, for 15 mins, before
adding BK (10 nM) (Fig. 13). As the resuits show, Hoe-140 was without effect on
retinal vesse! tone. More importantly, BK failed to di!ate the vesse!s pretreated with
Hoe-140 (p<O.Ol, n=7) when compared to the vasodilator effect of BK alone (Fig.
11). This suggests that B2 kinin receptors participate in BK-induced retinal
vasodilation.
120
100
$0
60
40
o
FIGURE 13. B2 kinin receptors in BK induced control rat retinal vasodilation. A baseline
measure was obtained, then U-46619 (1cM) was used after 10 mins the second measurement was
done, Hoe-140 (10 uM) was applied and after 15 mils the third measurement was obtained, 3K
(10 nM) was used and final measurement was done. The effect of BK is suppressed by Hoe-140
(n=7).
1 M 10 uM lOnM
U-46619 Hoe-140 BK
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1.1.4. B1 RECEPTORANTAGONISM
b address further the question of whether or flot B1 receptors are involved in BK
induced retinal vesse! dilation, the foïlowing set of experiments were performed. We
used the B1 receptor specific antagonist, des-Arg’°-Hoe-140. Retinal vesse!s were
vasoconstricted by U-46619 (1 tM). Then, they were pretreated with des-Arg’°-Hoe
140 (10 1iM) for 15 mins before adding BK (10 nM) (Fig. 14). The resu!ts show that
des-Arg10-Hoe-140 was without effect on retina! vesse! tone. Nevertheless, in
contrast to the effect of Hoe-140, des-Arg10-Hoe-140 faiÏed to inhibit the effect of
BK (n=5). This suggests that BK-induced retina! vasodilation is flot mediated by the
B1 kinin receptor.
E
1Œ4
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FIGURE 14. ldnin receptors in 3K induced control rat retinal vasodilation. A baseline
measure was obtained, then U-46619 (1 11M) was used after 10 mins the second measurement was
done, des-Arg10-Hoe-140 (10 [KM) was applied and after 15 mins the third measurement was
obtained, 3K (10 nM) was used and final measurement was donc. The effect of 3K is suppressed
by des-Arg10-Hoe-140 (n=5).
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1.2. INTRACELLULARAND MEMBRANE PATHWAYS WHICH
MEDIATE THE MNIN EVOKED VASODILATION IN CONTROL
RATS
In the following series of experiments, the intracellular and membrane pathways
which mediate the effect of BK were investigated. b identify these signal
transduction pathways we used a battery of signal transducer inhibitors.
1.2.1. G0/G1-PROTEINS
Using NF023 we investigated the participation of G0/G1-proteins in the vasodilation
evoked by BK. Retinal vessels were vasoconstricted with U-46619 (1 !IM). Then,
they were pretreated with NF023 (100 tM) for 25 mins before adding BK (10 nM)
(fig. 15). The resuit shows that Nf023 was without effect on retinal vessel diameter,
and that BK failed to dilate these vessels (p<O.Ol, n=4) when compared to the
vasodilator effect of BK in the absence of Nf023 (Fig. 11). This demonstrates that
the vasodilator effect of BK is transduced by G0/G-proteins.
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FIGURE 15. G0/G-proteins in 13K induced control rat retinal vasodilation. A baseline measure
was obtained, then U-46619 (1M) was used after 10 mins the second measurement was done,
Nf023 (100 .tM) was applied and after 25 mins the third measurement was obtained, BK (10
nM) was used and final measurement was done. The effect of 13K is suppressed by NF023
r
1tM lOOuM lOnM
(n=4).
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1.2.2. NITRIC OXIDE SYNTHASE INHIBITION
To determine whether or flot NO mediates the BK evoked vasodilation, L-NAME
was used to inhibit NOS. Retinas were exposed to U-46619 to apply vascular toile.
Afterwards, the preparation was pretreated wïth L-NAME (100 tM), for 20 mins
before adding BK (1 nM) (Fig.16). The resuits obtained from these experiments
show that L-NAME was without effect on retinal vessel diameter. However, BK
induced a significant vasodilation (p<O.O5, n=5) in the retina. Therefore, NO is flot
involved in the vasodilator effect of BK in the retina.
FIGURE 16. Nitric oxide in BK induced control rat retinal vasodilation. A baseline measure
was obtained. Then, U-46619 (1tM) was used after 10 mins the second measurement was done.
After that , L-NAME (100 tM) was applied for 20 mins, then the third measurement was
obtained. Finally, 3K (1 nM) was used and the final measurement was donc. The vasodilator
effect of 3K is flot blocked by L-NAME. (tp<O.O5, n=5).
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1.2.3. CALCIUM CHANNEL BLOCKERS
Is Ca2 influx necessary for the BK evoked vasodilation? b address this question,
GdCÏ3 was used to block the Ca2 influx pathway of endothelial ceils. Retinas were
exposed to U-46619 to provide a tone to vessels. Then, they were treated with GdCI3
(10 mM) for 15 mins before addition of BK (1 nM) (Fig. 17). The resuits show that
GdCI3 was without effect on retinal vessel tone compared to the vasoconstrictor
effect of U-46619. However, BK induced a significant vasodilation (p<O.05, n=5).
This suggests that Ca2 influx is flot required for BK to induce vasodilation in the
retina.
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FIGURE 17. Extracellular calcium influx in BK induced control rat retinal vasodilation. A
baseline measure was obtained. Then, U-46619 (1 tM) was used after 10 mins the second
measurement was done. Afterwards, GdC13 (10 mM) was applied for 15 mins, then the third
measurement was obtained. Finally, BK(1 nM) was used and the final measurement was done.
The GdCI3 did flot block the effect of BK. (*p<O.05, n=5).
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1.2.4. 1P3-SENSITIVE INTRACELLULAR CALCIUM STORES
To verify whether 1P3-sensitive Ca2 stores are involved in the effect of BK, we used
BHQ. As BHQ was dissolved in ethanol, experiments were done to verify if the
same concentration of ethanol which was used as vehicle affects the retinal vessel
response to BK. Retinal vessels were vasoconstricted using U-46619 (1 pM).
Afterwards, retinas were pretreated with ethanol (0.0001%) for 10 mins before
adding BK (1 nM) (Fig. 18). When compared to the vasoconstrictor effect of U-
466 19 the results show that ethanol is not able to affect the diameter of these vessels,
and BK induces a significant vasodilation (p<0.05, n=5) in the presence of ethanol.
This shows that the ethanol vehicle does not affect retinal vessel responses to BK.
After these control studies, BHQ was tested on the retina (fig. 19). Following
treatment with U-46619 (1 iM), retinas were pretreated with BHQ (1 iM) for 10
mins before the addition of BK (1 nM). As the resuits show, BHQ does flot change
the diameter of vessels when compared to U-46619. Moreover, the vasodilator effect
of BK was inhibited by BHQ (p.<O.Ol, n=6) (Fig. 11), which suggests that the release
of Ca2 from 1P3-sensitive intracellular Ca2 stores is implicated in the vasodilator
effect of BK.
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fIGURE 18. Ethanol (vehicle for BHQ) in 3K induced control rat retinal vasodilation. A
baseline measure was obtained. Then, U-46619 (1 &M) was used after 10 mins the second
measurement was done. Afterwards , ethanol (1OE4%) was applied for 10 mins, then the third
measurement was obtained. finatly, 3K (1 nM) was used and the final measurement was done,(*p<o.o5,
n=5).
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FIGURE 19. 1P3-sensitive intracellular calcium stores in 3K induced control rat retinal
vasodilation. A baseline measure was obtained. Then, U-46619 (1 M) was used after 10 mins
the second measurement was donc. Afterwards, BHQ (1 tM), was applied for 10 mins, then the
third measurement was obtained. Finally, 3K (1 nM) was used and the final measurement was
donc (n=6).
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1.2.5. NON-1P3-SENSITIVE INTRACELLULAR CALCIUM STORES
In the following set of experiments, cADP-ribose was used to investigate the role of
1P3-insensitive intracellular Ca2 p001 in BK-induced rat retinal vasodilation. Retinal
vessels were vasoconstricted by U-46619 (1 tM). Then, the vessels were treated with
cADP-ribose (10 M) for 25 mins before addition of BK (lOnM) (Fig.20). The
resuits show that cADP-ribose does flot affect the diameter of the vessels compared
to the vasoconstrictor effect of U-46619. Morever, the vasodilator effect of BK is
blocked (p<O.Ol, n=5) when compared to the vasodilator effect of BK alone (Fig.
11). This suggest that 1P3-insensitive intracellular Ca2 poois are implicated in the
effect of BK.
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FIGURE 20. Non-1P3-sensitive intracellular calcium stores in BK induced control rat retinal
vasodilation. A baseline measure was obtained. Then, U-46619 (1 1iM) was used after 10 mins the
second measurement was done. Afterwards , cyclic ADP-ribose (10 M), was applied for 25 mins,
then the third measurement was obtained. Finally, BK(10 nM) was used and the final measurement
was done (n=5).
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1.2.6. COX-2 INifiBITORS
b determine whether or flot products of the cyclooxygenase pathway are involved
in the retinal vasodilator effect of BK, we used L-745.337, a specific COX-2
inhibitor. As L-745.337 is soluble in DMSO, control experiments were done to
verify that a same concentration of DMSO as was used for a vehicle does flot affect
retinal vesse! tone. Retina! vessels were vasoconstricted by U-46619 (1 tM). Then,
they were treated with DMSO (0.0015%) for 30 mins before addition of BK (1 nM)
(Fig. 21). The resuits show that DMSO does flot affect vessel diameter, and that BK
can induce vasodilation (p<0.05, n=3). In the second set of experiments, retinal
vessels were vasoconstricted using U-46619 (1 tM). Then, they were pretreated with
L-745.337 (1 tM) for 30 mins before adding BK (1 nM) (Fig.22). The resuits show
that L-745.337 does flot affect the diameter of vesse!s. Moreover, BK can flot induce
retinal vesse! dilation (p<0.01, n=$) when compared to the vasodi!ator effect of BK
in the absence of L-745.337 (Fig. 11). This suggests that the cyc!ooxygenase
pathway is involved in the retina! vasodi!ator effect of BK.
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fIGURE 21. DMSO (vehichie for L-745.337) in BK induced control rat retinal vasodilation.
A baseline measure was obtained. Then, U-46619 (1 iM) was used after 10 mins the second
measurement was done. Mterwards, DMSO (15x i0 %) for 30 mins was applied, then the third
measurement was obtained. Finally, 3K (1 nM) was used and the final measurement was donc.
The effect of BK is present. (*p<O.05, n=3).
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FIGURE 22. The COX-2 pathway in 3K induced control rat retinal vasodilation. A baseline
measure was obtained. Then, U-46619 (111M) was used after 10 mins the second measurement
was donc. Afterwards, L-745.337 for 30 mins was applied, then the third measurement was
obtained. Finally, BK (1 nM) was used and the final measurement was donc (n=8).
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1.2.7. PROSTACYCLIN SYNTHASE INHIBITORS
To verify whether or flot PGI2 is iflvolved hi the retiflal vasodilator effect of BK we
used TPC. Retinal vessels were vasoconstricted with U-46619 (1 tM). Then, they
were pretreated with TPC (5 tM) for 25 mins before adding BK (1 nM) (Fig. 23).
The resuits show that TPC did flot affect the diameter of vessels. Morever, BK was
flot able to dilate retinal vessels (p<O.O1, n=6) when compared to the vasodilator
effect of BK in the absence of TPC (Fig. 11). This suggests that PGI2 is implicated in
the vasodilator effect of BK in the retina.
z
2
FIGURE 23. Prostacyclin in BK induced control rat retinal vasodilation. A baseline measure
was obtained. Then, U-46619 (1tM) was used after 10 mins the second measurement was
done. Afterwards, TPC (5 tM) for 25 mins was applied, then the third measurement was
obtained. Finally, BK (1 nM) was used and the final measurement was donc (n=6).
lpM 5iM mM
U-46619 TPC BK
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In summary, our data from the control rat group show that:
j) BK dilates retinal vessels and Hoe-140 inhibits the vasodilation induced by BK,
ii) des-Arg9-BK is without effect on retinal vessel diameter,
iii) the vasodilator effect of BK is mediated by stimulation of B2 receptors, but flot B1
receptors,
iv) the signal initiated via stimulation of B2 receptors by BK is transduced by
G0/G-proteins,
y) NO and extracellular Ca2 influx are flot involved in the effect of BK,
vi) the products of the cyclooxygenase pathway are involved in the retinal
vasodilator effect of BK,
vii) PGI2 mediates the vasodilation, and
viii) intracellular Ca2 pools from both 1P3-sensitive and 1P3 insensitive stores are
necessary for the vasodilator effect of BK.
1.3. STREPTOZOTOCIN-DIABETIC RAT
In this section, we will show the kinin effects on retinal vessel diameter in STZ
diabetic rats. Rats were made diabetic as described in section 11.1.1. Rats injected
with STZ but which did flot develop diabetes (blood glucose ranging from 5 to 10
mM) were taken as controls to verify any potential direct cytotoxic effect of STZ on
the retina. It should be stressed that those rats which became diabetic (blood glucose
>20 mM), did so as early as 1 day after injection of STZ.
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1.3.1. EFFECT 0F des-Arg9-BRADYMNIN ON RETINAL VESSEL TONE
To investigate what is the effect of des-Arg9-BK on SIZ-diabetic rat retinal vesse!
tone, rats were put into 6 separate groups. The first group received norma! saline
(contro! group), the second group were STZ-injected rats which did flot become
diabetic, and the other four groups are STZ-injected diabetic rats: 1 day, 4, 7 and 21
days after the administration of STZ. After each period of treatment, the eyes have
been prepared as was previously described. Retinas were exposed to U-46619 (1tM)
to app!y a tone to the vessels. Ten minutes later, des-Arg9-BK was used in seria!
concentrations ranging from 10 pM to 1 nM. The duration of treatment with des
Arg9-BK was for 15 mins (Fig.24). In the control group which received normal
saline (n=7) and in the STZ-injected non-diabetic rat group (n=5), des-Arg9-BK did
not affect the diameter of vessels when compared to the vasoconstrictor effect of U
46619. Mso, in 1 day STZ-injected diabetic rats, des-Arg9-BK did not affect the
diameter of the vesse!s (p>O.05, n=3) when compared to the vasoconstrictor effect of
U-46619. However, in the other groups, 4 days (n=6), 7 days (n=6), and 21 days
(n=5), des-Arg9-BK changed the diameter of the vesse!s significant!y (p<0.05) and
dose-dependently when compared to the vasoconstrictor effect of U-46619.
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1.3.2. EFFECT 0F BRADYMNIN ON RETINAL VESSEL TONE
The effect of BK on retinal vessel tone in STZ-diabetic rats was verified as follows.
STZ-diabetic rat retinal vessels were vasoconstricted with U-46619 (1tM ) for 10
mins. Then, BK (10 nM) was added. (fig 25). The resuits show that BK induces
relaxation in the retinal vessel when compared with the vasoconstrictor effect of U-
46619 (P<0.05, n=3). This resuit suggests that BK is able to change the diameter of
the vessels in STZ-diabetic rat.
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FIGURE 25. Effect of BK on STZ-diabetic rat retinal vessel diameter. A baseline measure was
obtained. Then, u-46619 (1tM) was used and the second measure was obtained, after that, BK
(lOnM) for 15 mins and the diameter of the vessels was measured (tP<O.05, nrz3).
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1.3.3. RESPONSE TO des-Arg9-BRADYMNIN FOLLOWING B1
RECEVTOR ANTAGONISM
For the purpose of identifying which receptor is stimulated by des-Arg9-BK on 21
day-STZ-diabetic rat retinal vessels to induce vasodilation, the B1 receptor specific
antagonist, des-Arg’°-Hoe-140, was used. The vessels were exposed to U-46619 (1
!IM) for 10 mins to apply tone. Then, they were pretreated with des-Arg10-Hoe-140
(1 tM) for 15 mins before adding des-Arg9-BK (1 nM) (Fig. 26). The resuits show
that des-Arg9-Hoe-140 does flot affect the diameter of the vessels compared to the
effect of U-46619. Moreover, des-Arg’°-Hoe-140 blocks the effect of des-Arg9-BK
(p<O.Ol, n=3), which demonstrates that the vasodilator effect of des-Arg9-BK in
retinal vesse! is mediated by B1 receptors.
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FIGURE 26. B1 kinin receptors in des-Arg9-BK induced 21 day-STZ-diabetic rat retinal
vasodilation. A baseline measure was obtained. Then U-46619 (1iM) was used after 10 mins the
second measurement was done, (des-Arg’°-Hoe-140) (1 tM) was applied after 15 mins the third
measurement was obtained , des-Arg9-BK (1 nM) was used and final measurement was donc (n=3).
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1.3.4. RESPONSE TO BRADYMNIN FOLLOWING B2 RECEPTOR
ANTAGONISM
To verify which receptor is stimulated by BK in STZ-diabetic rat retinal vessels to
induce vasodilation, we used the specific B2 receptor antagonist, Hoe-140. The
vessels were vasoconstricted by U-46619 (1tM) for 10 mins. Then, the vessels were
treated with Hoe-140 (10 tM) for 15 mins before adding BK (10 nM). As the data
show, Hoe-140 does flot affect the vessels compared to the effect of U-46619.
Moreover, Hoe-140 inhibits the effect of BK (p<O.Ol, n=4) (fig 27). This suggests
that the effect of BK is mediated by B2 receptors on retinal vessels of STZ-diabetic
rats.
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FIGURE 27. B2 kinin receptors in BK induced STZ-diabetic rat retinal vasodilation. A
baseline measure was obtained. Then U-46619 (1LM) was used after 10 mins the second
measurement was done, Hoe-140 (10 M) was applied after 15 mins the third measurement was
obtained, BK (10 nM) was used and final measurement was done (n=4).
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1.4. INTRACELLULAR AND MEMBRANE PATHWAYS WHICH
MEDIATE THE MNIN EVOKED VASODILATION IN STZ-DIABETIC
RATS
In the following series of experiments, we investigated the intracellular signais
which mediate the effect of des-Arg9-BK. To determine which signal transduction
pathways participate in this response we used a battery of inhibitors.
1.4.1. RESPONSE TO des-Arg9-BRADYMNIN FOLLOWING INHIBITION
0F G0/G-PR0TEINS
To investigate whether or flot G0/G-proteins are involved in the des-Arg9-BK-
induced retinal vasodilation we used NF023. Retinal vessels were vasoconstricted
using U-46619 (1 jtM). Then, they were treated with NF023 (100 tM) for 25 mins
before adding des-Arg9-BK (1 nM) (Fig. 28). The resuit shows that NF023 was
without effect on retinal vessel diameter when compared to the effect of U-46619,
and des-Arg9-BK failed to dilate the vessels (p.<0.O1, n=3) when compared to the
effect of des-Arg9-Bk in the absence of NF023 (Fig.24). This demonstrates that des
Arg9-BK-induced retinal vasodilation is mediated by G0/G-proteins.
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FIGURE 28. G0/G-proteins in des-Arg9-BK induced STZ-diabetic rat retinal vasodilation. A
baseline measure was obtained, then U-46619 (ltM) was used after 10 mins the second
measurement was done, NF023 (100 11M) was applied and after 25 mins the third measurement
was obtained, des-Arg9-BK (10 nM) was used and final measurement was done. The effect of des
Arg9-BK is suppressed by NF023 (n=3).
1 iM 100 iM mM
U-46619
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1.4.2. RESPONSE 10 des-Arg9-BR&DYKININ FOLLOWING NITRIC
OXIDE SYNTHASE INHIBITION
Does the response to des-Arg9-BK involve the release of NO in the retinal circulation
of the STZ-diabetic rat? To address this question, we used L-NAME. Retinas were
exposed to U-46619 to apply tone to the vessels. Afterwards, they were treated with
L-NAME (100 M) for 20 mins before adding des-Arg9-BK (1 nM) (Fig.29). The
results obtained from these experiments show that L-NAME was without effect on
retinal vessel diameter. Moreover, L-NAME failed to inhibit des-Arg9-BK-induced
retinal vessel dilation (j<0.05, n=3). These resuits suggest that this pathway is flot
involved in the vasodilator effect of des-Arg9-BK in the retina.
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FIGURE 29. Nitric oxide in des-Arg9-BK induced 7 day-STZ-dïabetic rat retinal vasodilation.
A baseline measure was obtained. Then, U-46619 (1tM) was used after 10 mins the second
measurement was done. Mter, L-NAME (100 IM) was applied for 20 mins, then the third
measurement was obtained. Finally, des-Arg9-BK (1 nM) was added and the final measurement
was done (p<O.OS, n3).
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1.4.3. RESPONSE TO des-Arg9-BRADYMNIN FOLLOWING CALCIUM
CHANNEL BLOCKADE
Does des-Arg9-BK induce retinal vasodilation by opening Ca2 channels? With the
aim to address this question we used GdC13. Retinas were exposed to U-46619 to
apply tone to vessels. Subsequently the vessels were treated with GdCÏ3 (10 mM) for
15 mins before the addition of des-Arg9-BK (1 nM) (Fig. 30). The resuits show that
GdCÏ3 was without effect on retinal vesse! diameter when compared to the
vasoconstrictor effect of U-46619. Moreover, GdC!3 fai!ed to inhibit des-Arg9-BK-
induced retinal vesse! di!ation (p<O.05, n=6). This suggests that Ca2 influx is not
involved in the vasodilator response to des-Arg9-BK.
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FIGURE 30. Extracellular calcium influx in des-Arg9-BK induced STZ-diabetic rat retinal
vasodilation. A baseline measure was obtained. Then, U-46619 (1iM) was used after 10 mins the
second measurement was done. Afterwards, GdC13 (10 mM) was applied for 15 mins, then the third
measurement was obtained. Finally, des-Arg9-BK (1 nM) was used and the final measurement was
done (n=6).
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1.4.4. RESPONSE TO des-Arg9-BRADYMNIN FOLLOWING
ANTAGONISM 0F 1P3-SENSITIVE INTRACELLULAR CALCIUM
STORES
Does des-Arg9-BK stimulate the 1P3 pathway to release Ca2 from the endoplasmic
reticulum to affect retinal vessels? b verify whether 1P3-sensitive Ca2 stores are
involved in the effect of BK, we used BHQ. As BHQ is soluble in ethanol, control
experiments were done to verify if concentrations of ethanol equal to what was used
as vehicle affects the retinal vessel response to des-Arg9-BK. Retinal vessels were
vasoconstricted with U-46619 (1 tM). Afterwards, retinas were pretreated with
ethanol (0.0001%) for 10 mins prior to the addition of BK (1 nM) (Fig 31). The
results show that this concentration of ethanol is not able to affect the diameter of the
vessels when compared to the vasoconstrictor effect of U-46619. Furthennore, des
Arg9-BK induced a significant vasodilation (p<O.05, n=4). This shows that ethanol
does flot affect the retinal vessel response to des-Arg9-BK. Once this was
established, BHQ was tested in the retinal circulation. After treatment with U-46619
(1tM), retinas were pretreated with BHQ (1 tM) for 10 mins before des-Arg9-BK (1
nM) was added. As the results show, BHQ did not change the diameter of the vessels
when compared to U-46619. Moreover, des-Arg9-BK dose not change the diameter
of the vessels (p<0.01, n=3) compared to the effect of des-Arg9-BK in the absence of
BHQ (Fig.24). This suggests that the release of Ca2 from 1P3-sensitive intracellular
Ca2 stores is implicated in the vasodilator effect of des-Arg9-BK (Fig.32).
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FIGURE 31. Ethanol (vehicle for BHQ) in des-Arg9-BK induced STZ-diabetic rat retinal
vasodilation. A baseline measure was obtained. Then, U-46619 (1cM) was used aftet 10 mins
the second measurement was done. Mterwards, ethanol (10%) was applied for 10 mils, then
the third measurement was obtained. Finally, des-Arg9-BK (1 nM) was used and the final
measuremen was done. (p<O.O5, n=4).
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FIGURE 32. 1P3sensitive intracellular calcium stores in des-Arg9-BK induced STZ-diabetic
rat retinal vasodilation. A baseline measure was obtained. Then, U-46619 (1tM) was used after
10 mins the second measurement was done. Afterwards, BHQ (1 tM), was applied for 10 mins,
then the third measurement was obtained. Finally, des-Arg9-BK (1 nM) was used and the final
measurement was done (n=3).
1 nM
des-Arg9-BK
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1.4.5. RESPONSE TO des-Arg9-BRADYMNIN FOLLOWING
ANTAGONISM 0F NON-1P3-SENSITIVE INTRACELLULAR
CALCIUM STORES
Do 1P3-insensitive intracellular Ca2 pools participate in the effect of des-Arg9-BK?
In the following set of experiments, cADP-ribose was used to investigate the role of
1P3-insensitive intracellular Ca2 pools in des-Arg9-BK-induced rat retinal
vasodilation. Retinal vessels were vasoconstricted using U-46619 (1 iM). Then, the
vessels were treated with cADP-ribose (10 tM) for 25 mins before addition of des
Arg9-BK (mM) (Fig. 33). The resuits show that cADP-ribose does flot affect the
diameter of vessels when compared to the vasoconstrictor effect of U-46619.
Moreover, the effect of des-Arg9-BK was blocked (p<O.Ol, n=4) when compared to
the effect of des-Arg9-BK in the absence of cADP-ribose (Fig. 24). This suggests
that 1P3-insensitive intracellular Ca2 pools are implicated in the effect of des-Arg9-
BK.
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FIGURE 33. Non-1P3-sensitive intracellular calcium stores in des-Arg9-BK induced STZ
diabetic rat retinal vasodilation. A baseline measure was obtained. Then, U-46619 (1 iM) was
used after 10 mins the second measurement was done. Afterwards, cyclic ADP-ribose (10 tM)
was applied for 25 mins, then the third measurement was obtained. Finally, des-Arg9-BK (1 nM)
was used and the final measurement was done (n=4).
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1.4.6. RESPONSE TO des-Arg9-BRADYMNIN FOLLOWING COX-2
INHIBITION
Are the products of the cyclooxygenase pathway involved in the retinal vasodilator
effect of des-Arg9-BK? For this purpose we used, L-745.337, a specific COX-2
inhibitor. The retinal vessels were vasoconstricted using U-46619 (1 cM). Then, they
were treated with L-745.337 (1 tM) for 30 mins before addition of des-Arg9-BK (1
nM) (Fig 34). The resuits show that L-745.337 does flot affect the diameter of these
vessels. Moreover, the effect of des-Arg9-BK was inhibited (p<0.01, n=4) when
compared to the effect of des-Arg9-BK alone (Fig.24). This demonstrates that the
cyclooxygenase pathway is involved in the retinal vasodilator effect of des-Arg9-BK.
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FIGURE 34. The COX-2 pathway in des-Arg9-BK induced STZ-diabetic rat retinal
vasodilation. A baseline measure was obtained. Then, U-46619 (1 tM) was used after 10 mins
the second measurement was done. Mterwards, L-745.337 (1 iM) for 30 mins was applied,
then the third measurement was obtained. finally, des-Arg9-BK (1 nM) was used and the final
measurement was done (n=4).
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1.4.7. RESPONSE TO des-Arg9-BRADYMNIN FOLLOWING
PROSTACYCLIN SYNTHASE INHIBITION
Is PGI2 involved in the retinal vasodilator effect of des-Arg9-BK? For this purpose,
we used TPC. Retinal vessels were vasoconstricted using U-46619 (1 1iM). Then,
they were treated with TPC (5 1iM) for 25 mins before addition of des-Arg9-BK (1
nM) (Fig. 35). The resuits show that TPC did not affect the diameter of these vessels.
Moreover, des-Arg9-BK was not able to dilate retinal vessels (p<O.Ol, n=6)
compared to the effect of des-Arg9-BK in the absence of TPC (Fig. 24). This
suggests that PGI2 is implicated in the vasodilator effect of des-Arg9-BK in the retina.
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FIGURE 35. Prostacyclin in des-Arg9-BK induced STZ-diabetic rat retinal vasodilation. A
baseline measure was obtained. Then, U-46619 (1tM) was used after 10 mins the second
measurement was done. Afterwards, TPC (5 iM) for 25 mins was applied, then the third
measurement was obtained. Finally, des-Arg9-BK (1 nM) was used and the final measurement was
done (n=6).
1M 5pM mM
U-46619 TPC des-Arg9-BK
63
In summary, our data from the STZ-diabetic rat group show that:
j) des-Arg9-BK induced vasodilation and this effect is mediated by B1 receptors,
ii) BK dilates retinal vessels and the vasodilator effect of BK is mediated by B2
receptors,
iii) the signal initiated by activation of B1 receptors by des-Arg9-BK is transduced by
G0/G-proteins,
iv) NO and extracellular Ca2 influx are flot involved in the effect of des-Arg9-BK,
y) the products of the cyclooxygenase pathway are involved in the retinal
vasodilator effect of des-Arg9-BK,
vi) PGI2 mediates the vasodilation, and
vii) intracellular Ca2 pools from both 1P3-sensitive and 1P3-insensitive stores are
necessary for the vasodilator effect of des-Arg9-BK.
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CHAPTER IV
DISCUSSION
In the present study, we investigated the function of kinins (BK and des-Arg9-BK) in
the retinal circulation of healthy and of SIZ-diabetic rats. Furthermore, using a
pharmacological approach we investigated the mechanisms which mediate the kinins
evoked vasodilation.
Previous studies have shown that the retina, choroid, ciliary body, iris and aqueous
humor of swine eyes contain enzymes capable of producing and inactivating kinins
(kallikrein and kininase I and II, respectively) v”. was demonstrated that the activity
of these enzymes varies in different eye structures, the highly vascularized tissues of
the retina and choroid have the highest actvities v”. Furthermore, the activity of tissue
as well as plasma kallikrein were studied in rabbit eye structures, and it was found
that activity of tissue kallikrein was higher than plasma kallikrein activity in iris,
ciliary body, vascular striatum, retina and conjunctiva . Moreover, molecular
studies using RT-PCR and Southern blot analysis of the key components of the
kallikrein-kinin system including tissue kallikrein, on human ocular tissues, have
detected LMWK, and kinin B1 and B2 receptors at high levels in human retina,
choroid and cillary body, and relatively low levels in the optic nerve 76 Mso, in situ
hybridization lias identified cellular localization of these four mRNAs in ocular
tissues. Such mRNA were also identified in endothelial cells of ocular blood vessels,
ciliary muscle and lens epithelial cells 76• These data demonstrate that the kallikrein
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kinin system is present in ocular tissues. A true understanding of the meaning of
these findings depends on knowing what is the function of this system in ocular
tissues. Furthermore, it is necessary to understand the function of this system under
physiological conditions and whether or not this system is involved in retinal
vascular complications associated with pathological conditions such as diabetic
retinopathy. Indeed, there was no study which addresses the role of the kinins in the
regulation of ocular circulation.
Our study is the first to investigate the potential role of kinins in the regulation of
retinal vesse! tone. The results from the experiments in the contro! group showed that
BK produces significant retina! vasodilation. The ability of such low concentrations
(100 pM) of BK to change the diameter of retina! vessels suggests that it can
function to regulate retinal vesse! tone. BK induced retinal vesse! relaxation with an
ED50 of approximately 250 nM which is in the same range of the Kd for B2 receptors
found in other tissues . A regu!atory ro!e of kinins on vesse! tone has been
demonstrated in other studies. There have been reports of e!evated b!ood pressure in
animais or humans genetically deficient in kailikrein, in animais treated acute!y or
chronica!!y with selective B2 receptors antagonists, and in geneticaiiy engineered
animais with a disrupted B2 receptor gene 87-$9 was demonstrated that loss of the B2
receptor in genetica!!y engineered mice causes a s!ight but significant rise in
systemic b!ood pressure Other studies demonstrated that ACE inhibition increases
kinin !evels in tissues and/or plasma Mso, there is a longstanding belief in the
literature that at !east a part of the beneficial effects of ANG 1-converting enzyme
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(ACE) inhibitors is derived from the potentiation of endogenous BK. These
inhibitors block one of the major inactivation pathways for kinins and lead the
kallikrein-kinin system to produce active metabolites instead of inactive
metabolites92. This pharmacology has been widely used in therapy for hypertension,
congestive heart failure, and myocardial infarction 91,92•
Furthermore, our study suggests that BK affects vesse! tone in diabetic rats.
Mtogether, BK not on!y p!ays the regu!atory role of the kallikrein-kinin system in
physiological states but also it cou!d affect the vesse!s in patho!ogica! states.
Consequent!y, the effect of BK may synchronize with the effect of the des-Arg9-BK
in pathologica! conditions and in this case, BK wou!d not p!ay a ro!e to re-establish
balance but it would produce a massive vasodi!ation early in the evolution of diabetic
retinopathy.
When we used 10 pM to 10 nM des-Arg9-BK in contro! rats, vesse! diameter was not
affected. It is known that des-Arg9-BK has a subnanomo!ar affinity for B1
receptors34. With this experiment we can suggest that the receptor B1 which is the
specific receptor for des-Arg9-BK is not expressed under norma! conditions. A full
verification of this possibility requires receptor studies based on mo!ecular bio!ogy
and radioligand-binding assays.
In the diabetic group, des-Arg9-BK induced a significant vasodilation at a
concentration of 10 pM. The vasodi!ation appeared with a de!ay of about 4 days in
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the SIZ-diabetic rat. It is in accordance with other studies which demonstrated that
in inflamed rat knee joints, following antigen-induced chronic arthritis, there was a
delay of about 1 to 5 days in plasma exudation due to kinin stimulated B1 receptors92.
In addition, it was found in a rat mode! of neuropathic hypersensitivity following
periphreal nerve injury, that the expression of B1 receptor mRNA was increased at 14
days post-injury in the site of nerve injury whi!e expression of mRNA for B2
receptors was a!ready present at 4$ h and was expressed bi!atera!!y at 14 days o”.
In our study, we also showed that BK dilates retinal vessels by activating B2
receptors in contro! and SIZ-diabetic rats. In contrast, des-Arg9-BK di!ated the
retina! vessels via the activation of B1 receptors only in STZ-diabetic rats. These are
in accordance with the literature which demonstrates that whi!e B2 receptors are
constant!y expressed by several tissues, B1 receptors are genera!!y flot expressed
under normal physiological conditions but are rapidly induced during pathologica!
situations such as diabetes The reports indicate that diabetes can upregu!ate B1
receptors through a PKC-activated NF-id3 following an autoimmunity response
associated with overproduction of cytokines including IL-lB and TNFŒ 96 and by
oxidative stress following hyperglycemia . Furthermore, the literature shows that
STZ, used to produce a mode! of insu!in-dependent diabetes mellitus, causes DNA
a!kylation and subsequent DNA strand breaks in pancreatic is!et ceils and induces an
insu!itis associated with cytokines which can upregulate B1 receptors By using RT
PCR analyses and in situ hybridization, it was demonstrated that endothelial ce!!s of
retina! b!ood vessels express mRNA for both Bi and B2 receptors 76 However, there
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was no investigation on the translation of the receptor protein or its insertion into the
celi membrane. It is possible that even if the B1 receptor mRNA is transcribed, it
would be partially translated or not translated at all because of its instability or an
uncoupling with intracellular transducers.
It is documented that kinin receptors activate G-proteins, Gaq/11 and GŒi, to
stimulate the intracellular pathways following interaction with their agonists (BK,
des-Arg9-BK) 16,64 Our resuits show that the vasodilatory effect of either B1 or B2
receptors are transduced by a G0/G-protein. More specific antagonists are needed to
make clear which classes are activated by kinin receptors in the retinal vessels.
Various signal transduction pathways have been described for kinins depending on
the cdl type 22,67-70• Our results from control and from STZ-diabetic rats show that the
release of NO and Ca2 influx are flot activated by BK or des-Arg9-BK. While, the
release of intracellular Ca2 from both 1P3-sensitive and 1P3-insensitive intracellular
Ca2 pools, and the release of PGI2 are stimulated by BK and des-Arg9-BK to induce
vasodilation in the retina. This is in accordance with previously reported data
showing that the cardiovascular effect of BK dependant vasodilator responses
depend on the release of AA from membrane phospholipids and increase of the
[Ca2] following stimulation of B2 receptors by BK . In other studies it was shown,
using isolated dog blood vessels, that the vasodilation induced by BK is mediated by
the release of PGI2 from endothelial celis Furthermore, COX-2 which is inducible
following a variety of stimuli including cytokines and immune complexes implicated
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in the pathogenesis of type I diabetes mellitus and upregulation of B1 receptors
96,100,101 suggests that both BK and des-Arg9-BK initiate a complex signalling
cascade that causes the release of AA in retinal vessels and consequently the release
of PGI2. This release of AA is dependent on the activation of cPLA2 mediated by a
G0/G1-protein. This enzyme is thought to be activated following stimulation by
agonists such as kinins, that also cause elevations of [Ca29 65• BK and des-Arg9-BK
increase the [Ca2] through its release from intracellular sources.
The present study shows the ability of kinins to induce retinal vesse! dilation, a
process that takes place in the ear!y stages of diabetic retinopathy. Changes in
vascu!ar flow and ca!iber begin very ear!y after weakening of blood vesse!s due to
pericyte degeneration in the ear!y stages of diabetic retinopathy. Pericyte
degeneration leads to the overproduction of cytokines and activation of NF-icB
which stimu!ates the kallikrein-kinin system and prornotes vasodi!ation.
Furthermore, data from other investigations show that endothe!ia! celi migration and
pro!iferation both in vivo and in vitro is enhanced by kinins, and that they may
promote the angiogenic cascade, with the eventual formation of new capi!!aries . It
was previously conc!uded that the tissue kallikrein and kinins have a role in the
sequential steps that form the angiogenic cascade !eading to the formation of new
b!ood vessels 102• Evidence for a role of B1 in reparative angiogenesis cornes frorn the
observation that the B1 gene expression is up-regu!ated by ischemia in ske!etal
muscle or myocardium 103,104 It was demonstrated that the endogenous B1 signaling is
essential for developing new blood vessels with functional relevance for recovery
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from ischemia’°5. There is a substantial body of evidence supporting a role for kinins
in the host defense response to ischemic injury Ail of these changes induced by
the kallikrein-kinin system in other tissues are the same as changes that may take
place during the development of diabetic retinopathy including neovascularization in
response to severe ischemia and hypoxïa of the retina. These findings reveal the need
for more investigation on the kallikrein-kinin system, and in particular its implication
in the later stages of diabetic retinopathy.
Our results suggest that the kallikrein-kinin system plays a crucial role in the
regulation of blood flow in the retina and this system could have a role in the early
stages of the development of diabetic retinopathy. The kinin system could be the
basis for a prophylactic approach to prevent the later complications of diabetes
mellitus in the retina. The action of kinins could be inhibited by the use of
antagonists or inhibitors to block the intracellular pathways which are stimulated by
kinin receptors or by the use of enzymes such as kininase il or angiotensin-I
converting enzyme, ACE.
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CONCLUSION
This is the first study which shows an effect of kinins in the retinal circulation. The
present study shows that : BK dilates retinal vessels in control and STZ-diabetic rats.
The vasodilator effect of BK is mediated by stimulation of B2 receptors. des-Arg9-
BK is without effect on retinal vessel diameter in control healthy rats, but it dilates
retinal vessels of STZ-diabetic rats and its effect is mediated by stimulation of B1
receptors. Neither the release of NO nor Ca2 influx are not involved. In contrast, the
release of PGI2 from AA and the increase of intracellular Ca2 derived from both 1P3-
sensitive and 1P3-insensitive intracellular Ca2 pools are implicated in the vasodilator
effect of BK and des-Arg9-BK.
These data suggest a function for kinins in the retinal circulation (fig.36). In healthy
rats, BK stimulates B2 receptors, whereas in STZ-diabetic rats des-Arg9-BK
stimulates B1 receptors and BK stimulates B2 receptors. Throughout, the signals are
transduced by G-proteins (G0/G) and the release of PGI2 from the AA. This release
is dependent on the activation of cPLA2. In addition, BK elevates intracellular Ca2
from both 1P3-sensitive and 1P3-insensitive Ca2 stores.
Control rats
t
• BK
.%
Prostacyctin synthetase1
Prostacyclin (PGI2)
Vasodilation
FIGURE 36. Summary of the effects of ldnins on retinal vessel. The intra retinal signal pathways
which are involved by the kallikrein-kinin system-induced retinal vessel vasodilation in control
and STZ-diabetic rats. BK, Bradykinin; des-Arg9-BK, des-Arg9-bradykinin; R , kinin Receptors;
GP, G-Protein; PLC, protein lipase C; PIP2, Phosphatidylinositol 4,5-diphosphate; 1P3, Inositol
triphosphate; RyR, Ryanodine receptor.
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